Invivyd Announces Appointment of Sara Cotter to Board Of Directors
28 July 2023 - 6:01AM
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical
company on a mission to protect the vulnerable from serious viral
infectious diseases, today announced the appointment of Sara Cotter
to its board of directors. Ms. Cotter brings extensive leadership
experience spanning healthcare investment management and drug
development.
“Ms. Cotter’s comprehensive knowledge of the biopharmaceutical
industry, pairing both operating and capital markets expertise,
make her an excellent addition to our board of directors,” said
Dave Hering, Chief Executive Officer of Invivyd. “Her keen industry
insights and impressive accomplishments in drug development and
healthcare investing will be invaluable to Invivyd as we advance
our lead candidate, VYD222, and our platform designed to generate a
stream of optimized antibodies to protect vulnerable people from
serious viral diseases.”
“I’m honored to join Invivyd’s board at such an exciting time,
with the company recently announcing positive initial Phase 1
VYD222 clinical data and plans to rapidly advance VYD222 into a
pivotal clinical trial that could support an emergency use
authorization (EUA) request for the prevention of symptomatic
COVID-19 in immunocompromised people,” said Sara Cotter. “I look
forward to working alongside my fellow board members and the
leadership team to advance Invivyd’s mission and unique,
platform-based approach to keeping pace with evolving viral
threats.”
Ms. Cotter is currently the Portfolio Manager for the UBS Global
Biotech Lux Fund as well as a Senior Investment Analyst on UBS
Asset Management’s Global Equity Team. Ms. Cotter rejoined UBS in
2022 after spending six years as Founder and Chief Executive
Officer (CEO) of Levo Therapeutics, Inc., a venture-backed biotech
company focused on developing impactful therapies for Prader-Willi
syndrome. During her tenure as Levo’s CEO, she oversaw all aspects
of the company’s late-stage advancement of intranasal carbetocin
(LV-101), as well as early-stage pipeline research. Ms. Cotter
started her investment career at UBS in 2007, and previously worked
at Abbott Laboratories (now AbbVie Inc.) in pharmaceutical
marketing, Northfield Laboratories in clinical development, and
Deutsche Bank Alex Brown in investment banking. Ms. Cotter received
an M.B.A from the Kellogg School of Management at Northwestern
University and a B.S. from the University of Notre Dame.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a
mission to rapidly and perpetually deliver antibody-based therapies
that protect vulnerable people from the devastating consequences of
circulating viral threats, beginning with SARS-CoV-2. Invivyd’s
technology works at the intersection of evolutionary virology,
predictive modeling, and antibody engineering, and is designed to
identify high-quality, long-lasting antibodies with the potential
to resist viral escape. The company is generating a robust pipeline
of product candidates which could be used in prevention or
treatment of serious viral diseases, starting with COVID-19 and
expanding into influenza and other high-need indications. Visit
https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “could,” “expects,”
“intends,” “potential,” “projects,” and “future” or similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements
include statements concerning, among other things, the company’s
ongoing research and clinical development plans and the timing
thereof, including with respect to advancing its lead candidate,
VYD222; the company’s plans to advance its platform designed to
generate a stream of optimized antibodies to protect vulnerable
people from serious viral diseases; the company’s plans to rapidly
advance VYD222 into a pivotal clinical trial that could support an
EUA request for the prevention of symptomatic COVID-19 in
immunocompromised people; the company’s mission and unique,
platform-based approach to keeping pace with evolving viral
threats; the company’s ability to rapidly and perpetually deliver
antibody-based therapies that protect vulnerable people from the
devastating consequences of circulating viral threats, beginning
with SARS-CoV-2; the potential for VYD222 and other product
candidates to be high-quality, long-lasting antibodies with the
potential to resist viral escape; the company’s plans to generate a
robust pipeline of product candidates which, if authorized or
approved, could be used in prevention or treatment of serious viral
diseases, starting with COVID-19 and expanding into influenza and
other high-need indications; and other statements that are not
historical fact. The company may not actually achieve the plans,
intentions or expectations disclosed in the company’s
forward-looking statements and you should not place undue reliance
on the company’s forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause the
company’s actual results to differ materially from the results
described in or implied by the forward-looking statements,
including, without limitation: the ability to gain complete
alignment with the applicable regulatory authorities on the
clinical trial design and development pathway for VYD222, including
the use of an immunobridging pathway in the U.S., and the timing
thereof; the timing and progress of the company’s discovery,
preclinical and clinical development activities, including the
company’s ability to rapidly advance VYD222 into a pivotal clinical
trial; the ability of the company to generate and utilize tools to
discover and develop a pipeline of antibodies to treat current and
potential future SARS-CoV-2 variants; the impacts of the COVID-19
pandemic on the company’s business and those of its collaborators,
the company’s clinical trials and its financial position;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials; the predictability of clinical success
of VYD222 or other product candidates based on neutralizing
activity in preclinical studies; the risk that results of
preclinical studies or clinical trials may not be predictive of
future results in connection with current or future clinical
trials; variability of results in models used to predict activity
against SARS-CoV-2 variants of concern; clinical trial site
activation or enrollment rates that are lower than expected;
changes in expected or existing competition; changes in the
regulatory environment; the uncertainties and timing of the
regulatory approval process, including the outcome of the company’s
discussions with regulatory authorities concerning its clinical
trials and platform-based approach to development; whether VYD222
or any other product candidate or combination of candidates is able
to demonstrate and sustain neutralizing activity against
predominant SARS-CoV-2 variants, particularly in the face of viral
evolution; whether VYD222 or other product candidates will be
high-quality, long-lasting antibodies with the potential to resist
viral escape; whether the company is able to successfully submit an
EUA in the future, and the outcome of any such EUA submission;
whether the company’s research and development efforts will
identify and result in safe and effective therapeutic options for
infectious diseases other than COVID-19; and whether the company
has adequate funding to meet future operating expenses and capital
expenditure requirements. Other factors that may cause the
company’s actual results to differ materially from those expressed
or implied in the forward-looking statements in this press release
are described under the heading “Risk Factors” in the company’s
Annual Report on Form 10-K for the year ended December 31, 2022
filed with the Securities and Exchange Commission (SEC), and in the
company’s other filings with the SEC, and in its future reports to
be filed with the SEC and available at www.sec.gov. Such risks may
be amplified by the impacts of the COVID-19 pandemic.
Forward-looking statements contained in this press release are made
as of this date, and Invivyd undertakes no duty to update such
information whether as a result of new information, future events
or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
Contacts
Media Contact:Kate Burdick, Evoke
Canale860-462-1569kate.burdick@evokegroup.com
Investor Contact:Chris Brinzey, ICR
Westwicke339-970-2843chris.brinzey@westwicke.com
Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From Apr 2024 to May 2024
Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From May 2023 to May 2024